文献速递消化道肿瘤与早癌消化内镜

苏格兰全国肠癌筛查项目从愈创木脂粪便隐血试验转为定量粪便免疫化学检测的首年效果

Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme.
PubMed 文献 · Gut · 2020-03-31

结果显示FIT参与率(63.9% vs 56.4%)和阳性率(3.1% vs 2.2%)更高,CRC阳性预测值更低(5.2% vs 6.4%),高风险腺瘤阳性预测值更高(24.3% vs 19.3%);FIT试点评估低估了参与率和阳性率,按评估阈值引入FIT导致结肠镜需求增加67.2%而非预测的10%。

要点

  • FIT参与率63.9%高于FOBT的56.4%,阳性率3.1%高于2.2%。
  • FIT对CRC的阳性预测值5.2%低于FOBT的6.4%,对高风险腺瘤的阳性预测值24.3%高于19.3%。
  • 按试点评估阈值引入FIT,结肠镜需求增加67.2%,远高于预测的10%。

核心结论

  • 从FOBT转为FIT提高了参与率和阳性率,CRC阳性预测值降低而腺瘤阳性预测值升高。
  • FIT试点评估低估了参与率和阳性率,按原阈值引入FIT导致结肠镜需求增加67.2%而非预测的10%。

主要发现

  • FIT总体参与率63.9%,FOBT为56.4%;FIT阳性率3.1%,FOBT为2.2%。
  • FIT检出更多CRC和腺瘤,但CRC阳性预测值FIT为5.2%、FOBT为6.4%。
  • 高风险腺瘤阳性预测值FIT为24.3%,FOBT为19.3%。
  • FIT试点评估中参与率58.5% vs FOBT 54.0%,阳性率2.5% vs 2.0%。

关键数值与推荐

  • FIT阳性阈值定义为80 µg Hb/g粪便。
  • FIT阳性率3.1%、FOBT阳性率2.2%;FIT对CRC的PPV 5.2%、FOBT 6.4%;FIT对高风险腺瘤的PPV 24.3%、FOBT 19.3%。
  • 按试点评估阈值引入FIT导致结肠镜需求增加67.2%,预测值为10%。

临床怎么用

  • 消化内科医生应知晓FIT筛查阳性者结肠镜需求可能远超试点预测,需提前规划内镜资源。
  • FIT阳性时CRC阳性预测值较低但高风险腺瘤阳性预测值较高,应重视腺瘤检出与随访。

局限性

  • 研究为筛查项目数据比较,非随机对照试验,可能存在人群和时期差异。
  • 未报告不同阈值下FIT性能的完整数据,仅基于80 µg Hb/g粪便阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Faecal immunochemical tests (FIT) are replacing guaiac faecal occult blood tests (FOBT) in colorectal cancer (CRC) screening. Data from the first year of FIT screening were compared with those from FOBT screening and assumptions based on a pilot evaluation of FIT. DESIGN: Data on uptake, positivity, positive predictive value (PPV) for CRC and higher-risk adenoma from participants in the first year of the FIT-based Scottish Bowel Screening Programme (n=919 665), with a threshold of 80 µg Hb/g faeces, were compared with those from the penultimate year of the FOBT-based programme (n=862 165) and those from the FIT evaluation (n=66 225). RESULTS: Overall, uptake of FIT was 63.9% compared with 56.4% for FOBT. Positivity was 3.1% and 2.2% with FIT and FOBT; increases were seen in both sexes, and across age range and deprivation. More CRC and adenomas were detected by FIT, but the PPV for CRC was less (5.2% with FIT and 6.4% with FOBT). However, for higher-risk adenoma, PPV was greater with FIT (24.3% with FIT and 19.3% with FOBT). In the previous FIT evaluation, uptake was 58.5% with FIT compared with 54.0% with FOBT; positivity was 2.5% with FIT and 2.0% with FOBT. CONCLUSION: Transition to FIT from FOBT produced higher uptake and positivity with lower PPV for CRC and higher PPV for adenoma. The FIT pilot evaluation underestimated uptake and positivity. Introducing FIT at the same threshold as the evaluation caused a 67.2% increase in colonoscopy demand instead of a predicted 10%.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Clark G, Strachan JA, Carey FA, et al. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme. Gut. 2020. PMID: 32234803. doi:10.1136/gutjnl-2019-320297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。